RT Book, Section
A1 Bauer, Larry A.
A2 Bauer, Larry A.
SR Print(0)
ID 3519839
T1 Chapter 7. Lidocaine
T2 Applied Clinical Pharmacokinetics, 2e
YR 2008
FD 2008
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-147628-7
LK accesspharmacy.mhmedical.com/content.aspx?aid=3519839
RD 2024/04/20
AB Lidocaine  is  a  local  anesthetic  agent  that  also  has  antiarrhythmic  effects.  It  is  classified  as  a  type  IB  antiarrhythmic  agent  and  is  a  treatment  for  ventricular  tachycardia  or  ventricular  fibrillation.1,2  For  episodes  of  sustained  ventricular  tachycardia  with  signs  or  symptoms  of  hemodynamic  instability  (angina,  pulmonary  edema,  hypotension,  hemodynamic  collapse),  electrical  cardioversion  is  the  treatment  of  choice.  However,  for  patients  who  are  more  hemodynamically  stable,  sustained  monomorphic  ventricular  tachycardia  due  to  myocardial  ischemia  or  infarction  may  be  successfully  treated  using  lidocaine  therapy.  Lidocaine  therapy  can  also  be  considered  for  the  treatment  of  polymorphic  ventricular  tachycardia  due  to  myocardial  ischemia  or  infarction.3